Xtandi seeks first-line status

Share this article:

The FDA gave Medivation and Astellas a boost by giving priority review to the partners' application to expand the prostate cancer drug's indication to include first-line status.

The drug is currently indicated for metastatic castration-resistant prostate cancer patients who have previously undergone chemotherapy and was approved in 2012.

PM Live notes that a pre-chemo indication will allow Medivation to provide early treatment competition for Janssen's prostate cancer drug Zytiga, which lassoed the pre-chemo approval in July 2013.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.